'Natural' hormone replacement and breast cancer risk: evidence for safety and efficacy
Labriola, D.; Pratt, K.; Bufi, P.
Oncology 23(7): 639-641
2009
ISSN/ISBN: 0890-9091 PMID: 19626834 Document Number: 636907
Document emailed within 1 workday
Related Documents
Ratanawichitrasin, A.; Reansuwan, W.; Ratanawichitrasin, S.; Bhodhisuwan, K.; Kongpatanakul, S. 2002: Risk of breast cancer in post-menopausal women using hormone replacement therapy Journal of the Medical Association of Thailand 85(5): 583-589Santen, R.J.; Pinkerton, J.; McCartney, C.; Petroni, G.R. 2001: Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy Journal of Clinical Endocrinology and Metabolism 86(1): 16-23
Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Gupta, G.; Aronow, W.S. 2002: Hormone replacement therapy. An analysis of efficacy based on evidence Geriatrics 57(8): 18-20; 23-24
Reynolds, T.M.; Wierzbicki, A.S. 2003: Does evidence-based medicine provide evidence? The evidence on breast cancer and the safety of oral contraceptives suggests that unorthodox interpretations may be just as valid Breast Journal 9(1): 66-67
Strnad, P. 1997: Hormone replacement and risk of breast carcinoma in a high-risk group of women Ceska Gynekologie 62(6): 355-361
Joseph, K.S. 1995: Breast cancer and hormone-replacement therapy New England Journal of Medicine 333(20): 1356; Author Reply 1357-1358
Rookus, M.A.; van Leeuwen, F.E.; Hamerlynck, J.V. 1998: Last word on hormone replacement and breast cancer? Nederlands Tijdschrift Voor Geneeskunde 142(3): 111-113
Li, L.; Ji, J.; Wang, J.-B.; Niyazi, M.; Qiao, Y.-L.; Boffetta, P. 2012: Attributable causes of breast cancer and ovarian cancer in china: reproductive factors, oral contraceptives and hormone replacement therapy Chinese Journal of Cancer Research 24(1): 9-17
Cobleigh, M.A.; Norlock, F.E.; Oleske, D.M.; Starr, A. 1999: Hormone replacement therapy and high S phase in breast cancer JAMA 281(16): 1528-1530
Fentiman, I.S. 2002: 20. Oral contraceptives, hormone replacement therapy and breast cancer International Journal of Clinical Practice 56(10): 755-759
Snyder, G.M.; Sielsch, E.C.; Reville, B. 1998: The controversy of hormone-replacement therapy in breast cancer survivors Oncology Nursing Forum 25(4): 699-706; Quiz: 707-708
Matsushita, H.; Wakatsuki, A. 2012: Hormone replacement therapy and cancer risk Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl 4): 805-809
Predná, L.; Habánová, M.; Sláviková, E.; Wyka, J. 2015: Hormonal contraceptives and hormone replacement therapy as a possible factor of breast cancer Roczniki Panstwowego Zakladu Higieny 66(3): 269-274
McCullough, M.; Weber, C.; Leong, C.; Sharma, J. 2013: Safety, efficacy, and cost savings of single parathyroid hormone measurement for risk stratification after total thyroidectomy American Surgeon 79(8): 768-774
Tavani, A.; La Vecchia, C.; Brinton, L.A.; McTiernan, A. 2001: Hormone replacement therapy and risk of endometrial cancer Tumori 87(5): S20-S21
This, P. 1996: Hormone replacement therapy in menopausal women previously treated for breast cancer Presse Medicale 25(4): 141-144
Schouten, L.J.; de Rijke, J.M.; Schlangen, J.T.; Verbeek, A.L. 1997: Hormone replacement therapy and high incidence of breast cancer between mammographic screens Lancet 349(9058): 1104
Tagashira, H.; Matsuhisa, T.; Oze, I.; Kiyoto, S.; Takahashi, M.; Hara, F.; Takabatake, D.; Takashima, S.; Aogi, K.; Osumi, S.; Eguchi, H. 2011: Efficacy and safety of aprepitant in patients with breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(8): 1307-1311
Yamamura, J.; Kamigaki, S.; Hamakawa, T.; Hoshino, H.; Nakata, K.; Yamamoto, T.; Ikeda, N.; Kawase, T.; Tsujie, M.; Kimura, Y.; Ozato, H. 2015: Efficacy and Safety of Pertuzumab for HER2-Positive Metastatic Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(6): 713-717